

- 23 Kyung Won Kim
- 24 Department of Pediatrics, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 25 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-2050; email: kwkim@yuhs.ac
- 26

27 Moo Suk Park

- 28 Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 29 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-1955; email: pms70@yuhs.ac
- 30

- 32 Department of Pharmacology, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 33 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-8755; email: HYGEE@yuhs.ac

³¹ Heon Yung Gee

34 **ABSTRACT**

35 **Background**

36 Chronic airway diseases like cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) pose

- 37 substantial clinical challenges. This study explores the p.C97W variant in *WFDC2*, proposed
- 38 as a new genetic origin of respiratory distress, especially among Koreans.

39 **Methods**

40 Whole-exome/genome sequencing (WES/WGS) were performed on 64 patients from 62 41 families presenting with severe bronchiectasis and chronic rhinosinusitis. *In vitro* analyses 42 and protein modeling were utilized to evaluate the functional implications of the *WFDC2* 43 variant.

44 **Results**

45 Pathogenic variants were found in 11.3% of families, including a novel homozygous *WFDC2* 46 missense variant (c.291C>G, p.Cys97Trp) in five unrelated families, confirmed by Sanger 47 sequencing. The variant, rare globally but more frequent in Koreans, caused persistent wet 48 cough, chronic rhinosinusitis, and bronchiectasis in affected patients. Lung tissue pathology 49 showed chronic inflammation and interstitial fibrosis. The p.C97W variant impaired WFDC2 50 protein folding, secretion, and function.

51 **Conclusions**

52 The p.C97W variant in *WFDC2* is a critical genetic factor in severe chronic airway disease 53 that shares clinical features with CF and PCD. Given its implications for diagnosis and 54 treatment, genetic testing for *WFDC2* mutations in individuals with CF or PCD-like 55 symptoms is recommended.

56 **INTRODUCTION**

57 In humans, the respiratory epithelium is critical for air transport, mucociliary clearance, and 58 immune regulation. The airway epithelium comprises various cell types, including basal, 59 ciliated, goblet, and club cells, as well as rare types like tuft cells, ionocytes, and 60 neuroendocrine cells.¹ The mucosal surface of the respiratory tract contributes to innate 61 immune defense. Each epithelial cell type plays a distinct role in maintaining airway integrity 62 and the mucociliary clearance system, by producing antioxidants, protease inhibitors, 63 antimicrobial peptides, or by secreting mucins and surfactants.^{2,3} Dysregulation of these 64 processes due to genetic or environmental factors can lead to the pathophysiology of severe 65 viral infections and chronic pulmonary disorders, including asthma, $1,4,5$ cystic fibrosis 66 (CF), $^{1,6-8}$ and primary ciliary dyskinesia (PCD). 1,9,10

67 In this study, we identified a homozygous missense variant (c.291C>G, p.C97W) in 68 *WFDC2*, a serine/threonine protease inhibitor with anti-bacterial activity, through whole-69 exome and genome sequencing in families affected by respiratory conditions resembling 70 PCD. Individuals with this variant exhibited chronic inflammation, bronchiectasis, interstitial 71 fibrosis, and infections caused by *Pseudomonas aeruginosa*. Due to its implications for 72 diagnosis and treatment, genetic testing for WFDC2 mutations is recommended for 73 individuals with CF or PCD-like symptoms.

74 **RESULTS**

75 **Identification of the** *WFDC2* **variant**

76 The WES or WGS analysis pipeline to identify the potential genetic causes in patients with 77 severe bronchiectasis and chronic rhinosinusitis ($n = 64$ from 62 families) is shown in Fig. S1. 78 Pathogenic variants were identified in 7 of the 62 families (11.3%): five with variants in 79 PCD-linked genes (six patients) and two (two patients) with CFTR variants (Fig. 1A, B). 80 Furthermore, a homozygous missense variant (c.291C>G, p.Cys97Trp) in *WFDC2* was 81 identified in five unrelated families (Fig. 1C, and Fig. S2). Sanger sequencing confirmed this 82 homozygous mutation in affected probands and their siblings, while the unaffected mother 83 was heterozygous (Fig. 1D). The allele frequency of this variant was 0.00001611 in the 84 global population 0.0004051 in East Asians, and 0.0018 in the Korean population, as reported 85 in the Genome Aggregation Database (gnomAD; Table S1). Haplotype analysis revealed that 86 individuals carrying the c.291C>G *WFDC2* mutation shared a genomic region of 87 approximately 138.5 kb surrounding the variant (Table S2). Subsequent haplotype analysis 88 using the LDhap Tool¹¹ using eight selected SNPs within the shared region revealed that 89 individuals with the c.291C>G *WFDC2* mutation share a rare H4 haplotype, with a frequency 90 of 0.63% in the homozygous state (Table S2). This finding suggests this variant as a founder 91 allele.

92

93 **Clinical phenotypes of individuals with the** *WFDC2* **variant**

94 All six patients from five unrelated families presented with persistent wet cough and chronic 95 rhinosinusitis (Fig. 2C). Chest CT scans revealed bronchiectasis in five patients, while one 96 patient (P1946-21) declined the scan (Fig. 2A). Pathological examination of the original lung 97 tissue from three female patients (P1969-21, P2678-21, and P2783-21) who underwent lung

5

98 transplantation at an average age of 33 years (range: 21–41 years; Table 1) revealed chronic 99 inflammation, bronchiectasis, and interstitial fibrosis (Fig. 2D). All patients had *P. aeruginosa* 100 lung infections, and pulmonary function demonstrated a severe airflow obstruction pattern 101 before lung transplantation. Two siblings (P5-21 and P5-22) of three male patients recently 102 visited our hospital, both presenting with bronchiectasis and reduced FEV1% predicted (Fig. 103 2B, and Table 1).

104 The average age at the onset of respiratory symptoms was 7.8 years (range, 1 month 105 to 13 years). Initial clinical diagnoses based on respiratory symptoms included neonatal 106 pneumonia in patients P1946-21 and P1969-21; bronchiectasis in patients P2678-21, P2783- 107 21, P5-21, and P5-22; and chronic rhinosinusitis in patients P5-21 and P5-22. Bronchiectasis 108 was confirmed during childhood in two-thirds of the patients, with one patient diagnosed at 109 late 0's (P2678-21) and three patients diagnosed at early 10's (P2783-21, P5-21, and P5-22). 110 The three patients who underwent lung transplants (P1969-21, P2678-21, and P2783-21) 111 have maintained stable lung structure and function for two, seven, and fourteen years, 112 respectively (Fig. 2, and Table 1).

113

114 **Effect of p.C97W variant on WFDC2 function**

115 As shown in Fig. 3A, WFDC2 contains a N-terminal signal peptide that is involved in 116 trafficking and secretion, and two whey acidic protein (WAP) domains connected by a short 117 loop. Each WAP domain includes eight cysteine residues that form four disulfide bonds. 118 Structure prediction using AlphaFold2¹² showed that C97 located in the second WAP domain 119 forms a disulfide bond with C109 (Fig. 3A). Multiple sequence alignments of human 120 WFDC2 with its orthologs from several vertebrate species demonstrated that both C97 and 121 C109 are highly conserved across vertebrates (Fig. 3B). Additionally, the *in silico* prediction

122 scores classified the C97W variant as pathogenic or disease-causing (Table S1).

123 Next, we predicted the structures of both the wild-type (WT) and p.C97W mutant *WFDC2* using ColabFold¹³ and AlphaFold2.¹² The p.C97W mutant failed to form a disulfide 125 bond with C109, in contrast to WT (Fig. 3C). Additionally, the bulky side chain of the Trp 126 (W) residue disrupted hydrogen bond formation near W97 in the second WAP domain (Fig. 127 3C). WFDC2 forms dimeric structures;¹⁴ therefore, we predicted the dimeric structures of WT 128 and p.C97W. Clustering of the structures from multiple AlphaFold2 runs showed that the 129 p.C97W structure predominantly exists in a 'trans–*trans*' configuration, where the second 130 WAP domain is untangled and interacts with the other subunit. In contrast, the WT WFDC2 131 dimers were more likely to exist in the '*cis*' configuration (Fig. 3C, and Fig. S3).

132 Assessment of the effects of the p.C97W mutant on WFDC2 secretion in human 133 embryonic kidney (HEK293T) cells overexpressing WT or p.C97W WFDC2 revealed that 134 WT WFDC2 produced a single band of approximately 24 kDa in both the lysate and culture 135 media. In contrast, the p.C97W variant was not secreted and showed reduced expression in 136 the lysate (Fig. 3D). Immunofluorescence analysis in HEK293T cells showed colocalization 137 of both WT and p.C97W WFDC2 with the endoplasmic reticulum marker, suggesting no 138 defect in intracellular localization (Fig. S4A). Furthermore, treatment with tunicamycin, an 139 inhibitor of N-linked glycosylation, or glycosidase digestion by incubation of cell lysates 140 with glycosidases, such as PNGase F or Endo H, demonstrated that both WT and p.C97W 141 were glycosylated (Fig. S4B, C), as indicated by the shift in band molecular weight with 142 no difference between the WT and mutant (Fig. S4B, C). This finding indicated that 143 WFDC2 was glycosylated, as previously described.¹⁴ In summary, these findings indicated 144 that the p.C97W mutation disrupts WFDC2 protein folding and secretion, impairing its 145 function.

7

146 **DISCUSSION**

147 In this study, we identified a novel *WFDC2* mutation (c.291C>G; p.C97W) as the causative 148 factor in severe lung disease. This autosomal recessive variant leads to chronic inflammation, 149 bronchiectasis, interstitial fibrosis, and severe airflow obstruction, often necessitating lung 150 transplantation. Population data from gnomAD and KRGDB indicate that this allele has a 151 relatively high frequency in East Asian populations, particularly in the Korean population. 152 Based on these data, approximately three out of one million individuals are homozygous for 153 this mutation, suggesting that around 150 individuals in South Korea could be affected. In 154 contrast, the previously reported c.145T>C; p.C49R variant, identified as a European founder 155 allele, is extremely rare in East Asian populations, including Koreans. However, it has a 156 higher frequency in the European population with an allele frequency of 0.0001814, 157 equivalent to three individuals per ten million and approximately 2,239 patients in Europe. 158 Additionally, 22 loss-of-function (LoF) alleles in *WFDC2* have been reported in gnomAD, 159 with a combined homozygous frequency of approximately 0.0000000003178.

160 Respiratory phenotypes of WFDC2 deficiency identified in our study and another 161 study¹⁵ present with clinical features that closely resemble CF and PCD, with symptoms 162 including bronchiectasis, chronic rhinosinusitis, and recurrent respiratory infections. Like CF, 163 patients with *WFDC2* mutations develop bronchiectasis across all lung lobes and are prone to 164 chronic *P. aeruginosa* infections, indicating a more severe and diffuse impact on lung 165 structure in WFDC2 deficiency and CF compared to PCD. Furthermore, nasal and sinus 166 abnormalities, including chronic rhinosinusitis and nasal polyps, are prevalent across all three 167 conditions. In this study, three patients with *WFDC2* mutations underwent lung 168 transplantation due to respiratory failure, further highlighting the severe progression of the 169 disease.

8

170 The *WFDC2* c.291C>G; p.C97W variant shares molecular similarities with the 171 previously described c.145T>C; p.C49R variant.¹⁵ Both are autosomal recessive missense 172 mutations in cysteine residues within the WAP domain, a critical region for disulfide bond 173 formation, and lead to LoF by disrupting the WAP domain. The key difference between the 174 two variants is that the p.C49R variant affects the first WAP domain, while the p.C97W 175 variant affects the second. Additionally, unlike the p.C49R variant, which is associated with 176 glycosylation defects, ¹⁵ our data did not reveal glycosylation differences for the p.C97W 177 variant, nor did it alter intracellular localization compared to the WT protein. Structural 178 modeling using AlphaFold2,¹² aligns well with the disruption of WAP domain integrity due to 179 the loss of disulfide bonds, suggesting that improper dimer formation might explain the 180 differences in the effects of the p.C97W variant. Despite these structural differences, both 181 variants exhibit similar defects in protein secretion, suggesting comparable pathological 182 consequences in humans.

183 In conclusion, we identified the p.C97W *WFDC2* variant as a novel cause of severe 184 chronic airway disease, which is physiologically distinct but clinically similar to CF and PCD. 185 Our study revealed the prevalence of the *WFDC2* p.C97W variant in the Korean population, 186 suggesting genetic testing for this gene could be beneficial in patients who have respiratory 187 phenotypes resembling PCD or CF.

188 **METHODS**

189 **Study design**

190 This study was approved by the Institutional Review Board of Severance Hospital, Yonsei 191 University Health System (IRB #4-2013-0770 and #4-2024-0647). Written informed consent 192 was obtained from the patients for their participation in this study and the publication of their 193 clinical data. Sixty-four patients with severe bronchiectasis and chronic rhinosinusitis from 194 62 unrelated families were enrolled from both the PCD-like severe bronchiectasis and chronic 195 rhinosinusitis and lung transplantation cohorts at a single tertiary medical center in South 196 Korea. These patients met the European Respiratory Society guidelines for the clinical 197 diagnosis of $PCD₁₆$ which include symptoms such as persistent wet cough, chronic 198 rhinosinusitis, or bronchiectasis. Whole-exome sequencing (WES) or whole-genome 199 sequencing (WGS) was performed to identify potential genetic causes. In-depth genetic 200 analyses were performed on individuals without any potential molecular causes.

201

202 **Analysis of whole exome/genome sequencing data**

10 203 Genomic DNA was extracted from blood samples of patients clinically suspected of having 204 PCD using a DNeasy Kit (Qiagen, Germany). Whole exome sequencing (WES) was 205 performed using a SureSelect V5 kit (Agilent Technologies, Santa Clara, CA, USA) and an 206 Illumina HiSeq 2500. Raw WES FASTQ files were imported into CLC Genomics Workbench 207 version 9.5.3 for data analysis. Sequenced reads were mapped to the human reference 208 genome, GRCh37/hg19. Variants were detected using the Basic Variant Caller of the CLC 209 Genomics Workbench, with a minimum coverage of 5, a count of 2, and a frequency of 20%. 210 Low-coverage whole genome sequencing (WGS) was performed using a PCR-free DNBSEQ 211 platform (BGI, Beijing, China). Following GATK best practice guidelines, the reads were

212 aligned to the human reference genome GRCh37/hg19 using the Burrows-Wheeler Aligner 213 (BWA-MEM). Duplicates were marked, reads were sorted, and the mapping quality was 214 recalibrated using PICARD-MarkDuplicates and GATK-BQSR. Variant calling of single 215 nucleotide variants (SNVs) and small insertions and deletions (indels) was performed using 216 GATK-HaplotypeCaller, and low-quality variants with a depth of coverage $(DP) < 5$ and 217 genotype quality $(GQ) < 20$ were filtered out. Copy Number Variation (CNV) analysis was 218 performed using EXCAVATOR version 2.2 and ExomeDepth (version 1.1.10) with default 219 settings for the WES data. For WGS data, CNVnator 220 (v0.3.2,https://github.com/abyzovlab/CNVnator) and GATK-SV 221 (https://github.com/broadinstitute/gatk-sv) were used to detect CNV. Mitochondrial variants 222 and transposable element insertion calling were performed using Mutect2 and xTea (v0.1.9; 223 https://github.com/parklab/xTea).

11 224 SNVs and small indels were annotated using Variant Annotation tools in the CLC 225 Workbench or ANNOVAR software. SNVs and small indels were first filtered based on 226 minor allele frequency (MAF), applying a threshold of MAF \lt 1% according to the Single-227 Nucleotide Polymorphisms Database (dbSNP), Genome Aggregation Database (gnomAD), 228 and Korean Reference Genome Database (KRGDB); variants that were nonsynonymous or 229 located in splice sites were selected. To evaluate pathogenicity and prioritize the candidate 230 causing variants, *in silico* prediction algorithms, such as MutationTaster, Sorting Tolerant 231 from Intolerant (SIFT), Combined Annotation Dependent Depletion (CADD), Polymorphism 232 Phenotyping v2 (PP2) scores, and public databases including Online Mendelian Inheritance 233 in Man (OMIM) and ClinVar, were used. Interpretation of the variants was performed 234 according to the American College of Medical Genetics and Genomics (ACMG) guidelines. 235 To identify splice site variants, SpliceAI was run on the variants using Ensembl's Variant

236 Effect Predictor (VEP) tool and filtered using a threshold MAF of 1% and delta score 237 threshold of 0.1. Variants were annotated based on their presence in human candidate cis-238 regulatory elements, as identified using the SCREEN database from the Encyclopedia of 239 DNA Elements (ENCODE) project. Confirmation of the detected variants was performed 240 manually using the Integrative Genomics Viewer (IGV) and through segregation analysis 241 using Sanger sequencing.

242

243 **Structural prediction and clustering**

244 AlphaFold2¹² and ColabFold¹³ were used to construct the *de novo* monomer and dimer 245 WFDC2 structures, respectively. The AlphaFold2-multimer-V2 algorithm was applied 246 without using a template or minimization, using three recycle number parameters in 247 ColabFold. The full-length WT or p.C97W human WFDC2 sequence was used as input. To 248 generate different structural conformations, multiple runs were conducted using different seed 249 values in ColabFold software. A total of 100 different structures were generated for the WT 250 monomer. C97W, homodimer WT, and p. C97W. The monomer and dimer structures were 251 then structurally aligned to perform principal component analysis (PCA) using the bio3d 252 package¹⁷ in R. The *K*-means algorithm was implemented to cluster the structures. The 253 optimal number of clusters suggested by R. Chimera X^{18} was used to visualize protein 254 structures.

255

256 **Cell culture, plasmids, and transfection**

12 257 Human embryonic kidney (HEK) 293T cells (#CRL-3216, American Type Culture Collection, 258 Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) 259 supplemented with 10% fetal bovine serum and penicillin (50 IU/mL)/streptomycin

260 (50 μg/mL; Invitrogen, Waltham, MA, USA). The cells were incubated in a 5% $CO₂$ 261 environment at 37[°]C.

262 Plasmids encoding human *WFDC2* (NM_006103.4) and mouse *Wfdc2* 263 (NM_026323.2, isoform 1 and NM_001374655.1, isoform 2) were purchased from OriGene 264 (Rockville, MD, USA). The coding sequences were amplified by PCR and subcloned into the 265 pcDNA3.4 vector using XbaI and AgeI sites. During PCR, 10xHIS tags were inserted directly 266 into the 3′ end in front of the stop codon. Human and mouse *WFDC2* mutants were 267 introduced using the QuikChange mutagenesis method (Agilent Technologies). The pEYFP-268 ER plasmid was purchased from NovoPro Biosciences (San Diego, CA, USA).

269 HEK293T cells were seeded in 6-well plates the day before transfection. Plasmids 270 were transfected using a PEI-MAX transfection reagent (Polysciences, Warrington, PA, USA) 271 according to the manufacturer's protocol. A total of 0.5 μg of the desired plasmid and 2 μL of 272 PEI-MAX was used for transfection. Cells were used for experiments 24–48 h post-273 transfection.

274

275 **Immunoblotting**

276 Forty-eight hours after transfection, HEK293T cells were washed twice with phosphate-277 buffered saline (PBS) and harvested in a lysis buffer containing 150 mM NaCl, 50 mM Tris-278 HCl (pH 7.4), 1 mM EDTA, 1% Triton X-100, and 1x protease inhibitor cocktail 279 (#04693116001, Sigma-Aldrich, St. Louis, MA, USA). The cells were then briefly sonicated 280 to break the cell membrane and homogenize the sample. Bradford assay was performed to 281 measure the protein concentration at an absorbance of 595 nm. Cell lysates (40–60 μg) were 282 used for analysis.

283 The samples were incubated in 2x sodium dodecyl sulfate (SDS) sample buffer

284 containing dithiothreitol (DTT, 0.02 g/mL) for 30 min at room temperature and subsequently 285 separated using SDS-polyacrylamide gel electrophoresis (PAGE). The separated proteins 286 were transferred onto a nitrocellulose membrane (GE Healthcare, Chicago, IL, USA), which 287 was blotted using suitable primary antibodies and horseradish peroxidase-conjugated 288 secondary antibodies in 5% skimmed milk. Protein bands were visualized using the 289 SuperSignal West Pico kit (Thermo Fisher Scientific) and a blue film (Afga, Belgium). The 290 density of each protein band was quantified using the ImageJ software (https://imagej.net/ij/). 291 To detect secreted WFDC2 proteins, transfected cells were incubated in a serum-free 292 medium for 24 h. Culture media were collected and concentrated using Amicon Ultra-4 filters

293 (Millipore, Burlington, MA, USA). The concentrated media was directly heated with 2x SDS 294 sample buffer with DTT and subjected to SDS-PAGE.

295 The following primary and secondary antibodies were used: anti-HIS (#2365, Cell 296 Signaling Technologies, Danvers, MA, USA; 1:1000 dilution), anti-ALDOA (#sc-390733, 297 Santa Cruz Biotechnology, Santa Cruz, TX, USA; 1:000 dilution), HRP Anti-beta Actin 298 antibody (#ab20272, Abcam, Cambridge, UK; 1:2000 dilution), goat anti-rabbit IgG 299 polyclonal antibody (HRP conjugate) (#ADI-SAB-300-J, Farmingdale, Enzo Life Sciences, 300 NY, USA), and goat anti-mouse IgG F(ab')2 polyclonal antibody (HRP conjugate) (#ADI-301 SAB-100-J; Enzo Life Sciences; 1:1000 dilution).

302

303 **Immunocytochemistry**

14 304 Transfected HEK293T cells were cultured on an 18 mm round coverslip. Cells were washed 305 twice with PBS, fixed with 4% paraformaldehyde for 10 min, again washed twice with PBS, 306 and permeabilized with 0.15% Triton X-100 in PBS for 10 min. The cells were washed twice 307 with PBS and incubated with a blocking buffer consisting of 5% donkey serum for 1 h at

308 room temperature. After blocking, the cells were incubated with the appropriate primary 309 antibodies for 1 h at room temperature and washed three times with PBS. Subsequently, the 310 cells were stained with secondary antibodies conjugated to a fluorescent marker for 1 h at 311 room temperature and washed thrice with PBS. The samples were mounted onto glass slides 312 using a mounting medium (Agilent Dako, CA, USA), and images were captured using a 313 confocal microscope (LSM 700, Carl Zeiss, Germany) equipped with a 40× objective lens.

314 The following primary and secondary antibodies were used: anti-HIS (#2365, Cell 315 Signaling Technologies; 1:200 dilution), Alexa Fluor 594 donkey anti-rabbit (#A21207, 316 Invitrogen; 1:400 dilution), Alexa Fluor 647 Phalloidin (#A22287, Invitrogen; 1:400 dilution).

317

318 **Deglycosylation assay**

319 Two methods were used to determine the glycosylation state of WFDC2. After transfection, 320 cells were treated with 2 μM tunicamycin (Sigma-Aldrich) for 20 h. A higher dose or longer 321 incubation time with tunicamycin caused excessive cell death, preventing further analysis. 322 The cells were harvested and subjected to SDS-PAGE, followed by immunoblotting. 323 Transfected cells were denatured in 2x SDS sample buffer containing DTT. Denatured 324 samples were incubated with PNGase F or Endo H (New England Biolabs, Ipswich, MA, 325 USA) according to the manufacturer's protocol. Deglycosylated samples were analyzed using 326 SDS-PAGE and immunoblotting. The shift in protein size was analyzed using both methods.

327 **FUNDING AND SUPPORT**

- 328 This work was supported by the National Research Foundation (NRF) grants funded by the
- 329 Korean government (2018R1A5A2025079 and RS-2023-00261905 to H.Y.G. and the Korea
- 330 Mouse Phenotyping Project RS-2024-00400118 to H.Y.G.). This work was supported by the
- 331 National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
- 332 (No. 2022R1A2C1010462 to K.W.K.).

333

334 **COMPETING INTERESTS**

- 335 The authors declared that no conflicts of interest.
- 336

337 **ACKNOWLEDGEMENTS**

- 338 We thank the families that participated in this study. We also thank the Yonsei Advanced
- 339 Imaging Center and Carl Zeiss Microscope.

340 **REFERENCES**

- 341 342
- 343 344 345
- 346 347
- 348 349 350
- 1. 2. Davis JP, Wholey 1. Davis JP, B. B. R. Bals R. The innate immune function of airway epithelial cells in

1. Davis JP (1. Bals R. The innate immune function of airway Remodeling.

1.0.11 83/99031936.00141514.

1.0.11 Iliemstra PS, McCray PB, Jr., Bals R. The innate immune function

Iliemstra PS, McCray PB, Jr., Bals R. The innate immune function

Inflammatory Ung disease. Eur Respir J 20

10.1183/09031936.00141514.

Lee S-N, Yoon J-H. 351 352 353
- 354 355
- 356 357
- 358 359
- 360 361 362
- 363 364
- inflammatory lung disease. Eur Respir J 2015;45(4):1150-62. DOI:

10.1183/09031936.00141514.

2. Lee S-N, Yoon J-H, The Role of Proprotein Convertases in Upper Airway Remodeling.

Motocules and Cells 2022:45(6):353-361. DO 10.1183/09031936.00141514.

10.1183/09031936.00141514.

Lee S-N, Yoon J-H. The Role of Proprotein Convertases in Upper Airway Remodeling.

Molecules and Cells 2022:45(6):353-361. DOI: https://doi.org/10.14348/molecles.2022 Lee S-N, Yoon J-H. The Ro

Molecules and Cells 2022;45(6

Jevnikar Z, Ostling J, Ax E,

phenotype with increased airw

DOI: 10.1016/j.jaci.2018.05.02

Vieira Braga FA, Kar G, Berg

states in health and in asthma

0468-5.
 Molecules and Cells 2022.45(6):353-361. DOI: https://doi.org/10.14348/moleels 2022.0019.

Jevnikar Z. Ostling J. Ax E. et al. Epithelial IL-6 trans-signaling defines a new asshma

phendype with increased alway inflammation Uevnikar Z. Ostling J. Ax E. et al. Epithelial II-6 trans-signaling defines a new asthm
phenotype with increased airway inflammation. J Allergy Clin Immunol 2019;143(2):577-59
DOI: 10.1016/j.jaci.2018.05.026.
Wivira Braga phenotype with increased airway inflammation. J Allergy Clin Immunol 2019;143(2):577-590.

DOI: 10.1016(ijaci 2018.05.026.

5. Veira Braga FA, Kar G, Berg M. et al. A cellular cenesus of human lungs identifies novel cell
 The Control of Spanis Control China Branch Vieira Braga FA, Kar G, Berg M, states in health and in asthma.
0468-5.
De Rose V, Molloy K, Gohy S, Pi
Fibrosis and COPD. Mediators In
Zoso A, Sofoluwe A, Bacchetta N
epithelial 0468-5.

De Rose V, Molloy K, Gohy S, Pilette C, Greene CM. Ainway Epithelium Dysfunction in Cystic

Fibrosis and COPD Mediators Infilarm 2018;2018:1309746. DOI: 10.1155/2018/1309746.

2018 A Sofolwev A, Bacchetta M, Chans De Rose
Fibrosis
Zoso A,
epithelia
Whitsett
2018;15
Leigh M
Dyskine:
DOI: 10.
Bustama
Perspec
Machiela
haplotyp
Bioinforr
Jumper
AlphaFo
Mirdita N
Protein f
Protein f
Dioinforr
Jumper
AlphaFo
Mirdita N
Protein f
Doise_I
Di 20so A. Sofoluwe A. Bacchetta M. Chanson M. Transcriptomic profile of cystic fibrosis ain
epithelial cells undergoing repair. Sci Data 2019;6(1):240. DOI: 10.1038/s41597-019-0256-
Whitsett JA Airway Epithelial Differentiat Whitsett JA A kirway Epithelial Differentiation and Mucociliary Clearance. Ann Am Thorac So
2018;15(Suppl 3):S143-S148. DOI: 10.1513/AnnalsATS.201802-128AW.
Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles
Dyskinesia (PCD): A genetic disorder of motile cilia. Transl Sci Rare Dis
DOI: 10.3233/TRD-190036.
Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Example: Marin XM, Ost
Bustamante-Marin XM, Ost
Perspect Biol 2017;9(4). DO
Machiela MJ, Chanock SJ.
haplotype structure and
Bioinformatics 2015;31(21):3
Jumper J, Evans R, Pritz
AlphaFold. Nature 2021;596
Mirdita M, Schut Machiela MJ, Chanock SJ. LDlink: a web-based application in haplotype structure and linking correlated alleles of Bioinformatics 2015;31(21):3555-7. DOI: 10.1093/bioinformatic Jumper J, Evans R, Pritzel A, et al. Highly ac 365 366 367
- 368 369
- pperion of 1010 math increased aircratic members with the DIS-3(1): 10.10168/space Wieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cellstates in health and in asthma. Nat Med 2019;2 states in health and in asthma. Nat Med 2019:25(7):1153-1163. DOI: 10.1038/s41591-019

6. De Rose V. Molloy K, Gohy S. Pilette C. Greene CM. Airway Epithelium Dystundion in Cystic

Filhres is and COPD. Mediators Inflamm 20 Fibrosis and COPD. Mediators Inflamm 2018;2018:1309746. DOI: 10.1155/2018/1309746.

Zose A, Scholave A, Bacchetta M, Chanson M. Transcriptomic profile of cystic fibrosis airway

epithelial cells undergoing repair. Sid Data repithelial cells undergoing repair. Sci Data 2019;6(1):240. DOI: 10.1038/s41597-019-0256-6.

Whitsett JA. Airway Epithelial Differentiation and Muccolilary Clearance. Ann Am Thorac Soc

2. Distants M, KSupp1 3): 3143-S148 2018;15(Suppl 3):5143-5148. DOI: 10.1513/AnnalsATS.201802-128AW

Leight MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary

Dyskinesia (PCD): A generic disorder of motile cilia. Transl Sci Rare 9. Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary
Dyskinesis (PCD): A genetic disorder of motile cilia. Transl Sci Rare Dis 2019.4(1-2):51-75.
10. Bustamante-Marin XM, Ostrowski LE. C DOI: 10.3233/TRD-190036.

DOI: 10.3233/TRD-190036.

Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. Cold Spring Harb

Perspect Biol 2017;9(4). DOI: 10.1101/cshperspect.a028241.

Machinal MJ, Chancek SJ. Perspect Biol 2017;9(4). DOI: 10.1101/cshperspect.a028241.

11. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific

haplotype structure and linking correlated alleles of possible fun 11. Machiela Machiela Michaela Michaela Michaela Michaela Michaela Michaela Michaela Music Solutional variants.

11. Jumper J. Evans R. Pritzel A. et al. Highly accurate protein structure prediction with

11. Machiela M. S minities 2015;31(21):3555-7. DOI: 10.1093/bioinformatics/btv402.
Bioinformatics 2015;31(21):3555-7. DOI: 10.1093/bioinformatics/btv402.
Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with Jumper J, Evans R, Pritzel A, et al. Highly accurate protein struction and AlphaFold. Nature 2021;596(7873):583-589. DOI: 10.1038/s41586-021-C
Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger N
protein fo AlphaFold. Nature 2021;596(7873):583-589. DOI: 10.1038/s41586-021-03819-2.

Mirdita M. Schutze K. Moriwaki Y. Heo L. Ovchinnikov S. Steinegger M. ColabFold: making

protein folding accessible to all. Nat Methods 2022;19(6) Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. Colabi
protein folding accessible to all. Nat Methods 2022;19(6):679-682. DOI: 10.1038/
01488-1.
Bingle L, Armes H, Williams D, et al. Expression and fu 370 13. Mirdita M, Schutze K, Mirdita M, Schutze K, Moriton M, Schutze A, Mulliams D, et al. Expression and function of murine WFDC2 in the respiratory tract. bioRxiv 2020:2020.05.05.079293. DOI: 10.1101/2020.05.05.079293.
The 371 372
- protein for all statements and the alleger of the control Bingle L,
respirator
Doughert_.
 373 14. Bingle L, Armes H, Armes H, Armes H, Armes H, Armes H, Mothe Menchen T, et al. Recessively Inherited Deficiency of
14. Bingle L, Armes H, Norwich of Menchen T, et al. Recessively Inherited Deficiency of
17. Bingle L, A 374
- respiratory GW, Ostrowski LE, Nöthe-Menchen T, et al. Recessively Inherited Defici
Dougherty GW, Ostrowski LE, Nöthe-Menchen T, et al. Recessively Inherited Defici 375 17. Dougherty Gw, Ostrowski Le, Nötherty American T, et al. Recently of al. Recently inherited Deficiency of a
17. Recently in the central Recently of al. Recently in the central Recently of al. Recently in the central Rec

376 Med 2024;210(1):63-76. (In eng). DOI: 10.1184/rocm 202308-13700C.

Lucas JS. Barbato A. Collins SA et al. European Respiratory Society guidelines for the

diagnosis of primary ciliary dyskinesia. Eur Respir J 2017;49(1). D 377 Lucas JS, Barbato A, Collins SA et al. European Respiratory Socialiagnosis of primary ciliary dyskinesia. Eur Respir J
10.1183/13993003.01090-2016.
Grant BJ, Rodrigues AP, ElSawy KM, McCammon JA, Caves LS. Bic
10.1083/bioi 378 diagnosis of primary ciliary dyskinesia. Eur Respir J 2017.49(1). DOI:
10.1183/13993003.01090-2016
17. Granti BJ, Rodrigues AP, ElSawy KM, McCammon JA, Caves LS. Bio3d: an R package for
the comparative analysis of protein 379 10.1183/13993003.01090-2016.

Grant BJ, Rodrigues AP, ElSawy KM, McCammon JA, Caves LS. Bio3d: an R package for

the comparative analysis of protein structures. Bioinformatics 2006;22(21):2695-6. DOI:

10.1093/bioinformati 380 Grant BJ, Rodrigues AP, ElSaw
the comparative analysis of p
10.1093/bioinformatics/btl461.
Pettersen EF, Goddard TD, Hu
researchers, educators, and
10.1002/pro.3943.
Waterhouse AM, Procter JB, Ma
sequence alignment editor 381 the comparative analysis of protein structures. Bionformatics 2006;22(21):2695-6. DOt
10. 1093/bioinformatics/btl461.
18. Petetsen EF, Goddard TD, Huang CC, et al. UCSF ChimeraX: Structure visualization for
researchers, ed 382 10.1093/bioinformatics/btM61.

Pettersen EF, Goddard TD, Huang CC, et al. UCSF ChimeraX: Structure visualization for

researchers, educators, and developers. Protein Sci 2021;30(1):70-82. DOI:

10.1002/pro.3943.

Waterhous 383 Pettersen EF, Goddard TD, Hesearchers, educators, a
10.1002/pro.3943.
Waterhouse AM, Procter JB, M
sequence alignment editor and
10.1093/bioinformatics/btp033. 384 18. Petersen EF, Frederick School of the developers. Protein Sci 2021;30(1):70-82. DOI:
19. Waterhouse AM, Procter J.B., Martin DM, Clamp M, Barton G.J. Jalview Version 2--a multiple
19. Waterhouse AM, Procter J.B., Martin 385 researchers, AM, Procter JB, Martin DM, Clamp M, Barton GJ, Jalview Version 2--a multiple
sequence alignment editor and analysis workbench. Bioinformatics 2009;25(9):1189-91. DOI:
10.1093/bioinformatics/btp033.
10.1093/bio 386 Waterhouse AM, F
sequence alignmer
10.1093/bioinforma
with the set of the set o 387 19. waterhouse AM, Processors Amazon, Statistical Martin D. Processors AM, Processors AM, 201
10. 1093/bioinformatics/btp033.
The M, Clamp M, 388 s_{S} sequence alignment exploration \mathcal{L}_{S} workbench. Biomatics 2009;25(9):1189-91. Doi:11993/bioinformatics/btp033. 389

10.1093/bioinformatics/btp033.

390

391 **FIGURE LEGENDS**

392

393 **Fig. 1. Identification of a homozygous variant in** *WFDC2* **in families with severe** 394 **bronchiectasis and chronic rhinosinusitis.**

395 (A, B) Summary and result of WES/WGS analysis to elucidate the causal variants in patients 396 with severe bronchiectasis and chronic rhinosinusitis. Five families had a homozygous 397 variant in *WFDC2*, which was the c.291C>G substitution resulting in the amino acid change 398 p.Cys97Trp. (C) Pedigree of five families with the c.291C>G *WFDC2* variant. The probands 399 are indicated using arrows. (D) Sanger sequencing result of c.291C>G *WFDC2* variant 400 representing individuals from three families. The altered amino acid is written in red. WES, 401 Whole exome sequencing; WGS, whole genome sequencing.

403 **Fig. 2. Clinical manifestation of individuals with bi-allelic** *WFDC2* **variant.**

20 404 (A) Radiologic findings of patients with progressive destructive lung diseases requiring lung 405 transplantation. Left panels display extensive cystic/cylindrical bronchiectasis with bronchial 406 wall thickening, fibrosis, and air trappings. Additionally, peribronchial and centrilobular

417

418 **Fig. 3. Molecular mechanism of** *WFDC2* **p.C97W mutant.**

419 (A) Overall structure of the WFDC2 protein. Two WAP domains and the disulfide bond-420 forming cysteines are shown. C97 forms a disulfide bond with C109. (B) Multiple sequence 421 alignment of human WFDC2 against its orthologs from five different vertebrate species was 422 performed using Jalview.¹⁹ The mutated amino acid residue (C97) and the disulfide bond-423 forming cysteine residue with C97 (C109) are indicated. (C) Monomer and homo-dimer 424 structure prediction of WFDC2 WT and p.C97W mutant by AlphaFold2.^{12,13} (D) Western blot 425 analysis of WT and p.C97W mutant WFDC2 proteins in both the lysates and secreted media 426 of HEK293T cells overexpressing the proteins. In (D), data are presented in mean \pm standard 427 error of the mean. In (D), a two-way Student's t-test was used to calculate the p-value, and a 428 p-value < 0.05 was considered significant. *, $p < 0.05$; ****, $p < 0.0001$.

Patient	P1946-21	P1969-21	P2678-21	P2783-21	P5-21	P5-22
Age at confirmation of WFDC2 mutation, years	$31 - 35$	$36-40$	$46 - 50$	$31 - 35$	$21 - 25$	$21-25$
Sex	Male	Female	Female	Female	Male	Male
Bronchiectasis	N/A	Yes	Yes	Yes	Yes	Yes
Psuedomonas aeruginosa infection	N/A	Yes	Yes	Yes	N/A	N/A
Chronic rhinosinusitis	Yes	Yes	Yes	Yes	Yes	Yes
Nasal polyposis	No	No	No	Yes	Yes	Yes
Age at transferred, years	26-30	$31 - 35$	36-40	$16-20$	$21 - 25$	$21-25$
Lung Transplantation (age, years)	No	Yes $(36-40)$	Yes $(41-45)$	Yes $(21-25)$	No	No
Medical history of siblings	Deceased due to pneumonia	N _o	Reduced lung function	No	Sibling of P5- 22	Sibling of P5- 21
Pulmonary function [®]						
$FEV1$ (% pred)	N/A	29	21	22	85	71
$FEV1$ (L)	N/A	0.86	0.56	0.69	3.55	3.14
$FEV1/FVC$ (%)	N/A	44	49	44	81	81
DLCO		37				

Table 1. Clinical characteristics of the patients

429 N/A, data not available

^{*} Pulmonary function tests were performed just before lung transplantation for P1969-21, P2678-21, and P2783-21, and most recently for P5-

431 1 and P5-2.